# UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

> **NCT05015972** · EARLY_PHASE1 · WITHDRAWN · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China**

## Conditions studied

- B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CTA30X UCAR-T injection

## Key facts

- **NCT ID:** NCT05015972
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-20
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No proper participant is found.
- **Last updated:** 2022-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05015972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05015972, "UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05015972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*